Welch Group’s GT Biopharma GTBP Stock Holding History

Welch Group’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-333	Closed	-$2.55K	–	237
2023 Q4	$2.55K	Hold	333	–	–	﹤0.01%	228
2023 Q3	$2.41K	Hold	333	–	–	﹤0.01%	215
2023 Q2	$3.12K	Hold	333	–	–	﹤0.01%	216
2023 Q1	$5.5K	Hold	333	–	–	﹤0.01%	215
2022 Q4	$8.86K	Hold	333	–	–	﹤0.01%	218
2022 Q3	$18K	Hold	333	–	–	﹤0.01%	178
2022 Q2	$30K	Hold	333	–	–	﹤0.01%	199
2022 Q1	$29K	Hold	333	–	–	﹤0.01%	213
2021 Q4	$31K	Hold	333	–	–	﹤0.01%	216
2021 Q3	$67K	Buy	+333	New	+$100K	﹤0.01%	188

Other funds holding GTBP

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Welch Group's GTBP Position: Q1 2024 in Review

Welch Group sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 333 shares — an estimated $2.55K sold.

Welch Group first reported a position in GTBP in Q3 2021 and held it in 10 quarters. The position peaked at $67K in Q3 2021. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

Welch Group reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
Welch Group sold 333 GT Biopharma shares in Q1 2024, an estimated $2.55K.
Welch Group first reported a position in GT Biopharma in Q3 2021 and held it in 10 quarters.
Welch Group's GT Biopharma position peaked at $67K in Q3 2021.
17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Welch Group's 13F filing for Q1 2024, filed 9 Apr 2024.